NovaBay Pharmaceuticals, Inc. (NYSE:NBY) Major Shareholder Poplar Point Capital Partners Buys 49,400 Shares

NovaBay Pharmaceuticals, Inc. (NYSE:NBY) major shareholder Poplar Point Capital Partners acquired 49,400 shares of the company’s stock in a transaction on Friday, March 28th. The stock was acquired at an average cost of $0.61 per share, for a total transaction of $30,134.00. Following the completion of the purchase, the insider now directly owns 950,000 shares of the company’s stock, valued at approximately $579,500. This represents a 5.49 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Poplar Point Capital Partners also recently made the following trade(s):

• On Friday, January 31st, Poplar Point Capital Partners purchased 70,685 shares of NovaBay Pharmaceuticals stock. The stock was acquired at an average cost of $0.65 per share, for a total transaction of $45,945.25.
• On Monday, January 27th, Poplar Point Capital Partners acquired 31,703 shares of NovaBay Pharmaceuticals stock. The shares were bought at an average cost of $0.69 per share, with a total value of $21,875.07.
• On Thursday, February 20th, Poplar Point Capital Partners bought 1,836 shares of NovaBay Pharmaceuticals stock. The stock was bought at an average price of $0.63 per share, for a total transaction of $1,156.68.
• On Tuesday, February 18th, Poplar Point Capital Partners purchased 3,222 shares of NovaBay Pharmaceuticals stock. The stock was bought at an average cost of $0.66 per share, with a total value of $2,126.52.
• On Monday, February 3rd, Poplar Point Capital Partners acquired 2,597 shares of NovaBay Pharmaceuticals stock. The shares were purchased at an average cost of $0.64 per share, for a total transaction of $1,662.08.
• On Friday, March 7th, Poplar Point Capital Partners purchased 102 shares of NovaBay Pharmaceuticals stock. The shares were purchased at an average cost of $0.55 per share, for a total transaction of $56.10.
• On Tuesday, March 4th, Poplar Point Capital Partners acquired 4,000 shares of NovaBay Pharmaceuticals stock. The stock was purchased at an average cost of $0.58 per share, with a total value of $2,320.00.
• On Thursday, February 27th, Poplar Point Capital Partners bought 385 shares of NovaBay Pharmaceuticals stock. The shares were purchased at an average cost of $0.61 per share, for a total transaction of $234.85.
• On Tuesday, February 25th, Poplar Point Capital Partners bought 25,033 shares of NovaBay Pharmaceuticals stock. The stock was acquired at an average cost of $0.62 per share, with a total value of $15,520.46.
• On Friday, March 14th, Poplar Point Capital Partners purchased 25,511 shares of NovaBay Pharmaceuticals stock. The shares were acquired at an average price of $0.63 per share, for a total transaction of $16,071.93.

NovaBay Pharmaceuticals Stock Up 5.4 %

NBY opened at $0.59 on Wednesday. NovaBay Pharmaceuticals, Inc. has a twelve month low of $0.36 and a twelve month high of $9.08. The company’s 50-day moving average price is $0.60 and its two-hundred day moving average price is $0.63. The stock has a market cap of $3.43 million, a price-to-earnings ratio of -0.01 and a beta of 0.90.

Analysts Set New Price Targets

Separately, StockNews.com began coverage on NovaBay Pharmaceuticals in a research note on Thursday, April 10th. They issued a “hold” rating for the company.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.